BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 208 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,597,170 | +8.3% | 649,318 | +7.7% | 0.01% | -12.5% |
| Q2 2023 | $4,245,745 | -9.4% | 603,089 | +7.3% | 0.01% | -11.1% |
| Q1 2023 | $4,687,588 | -28.1% | 562,061 | -1.0% | 0.01% | -30.8% |
| Q4 2022 | $6,519,480 | -9.8% | 567,918 | -1.0% | 0.01% | -23.5% |
| Q3 2022 | $7,227,000 | +16.4% | 573,577 | -2.3% | 0.02% | +21.4% |
| Q2 2022 | $6,209,000 | -33.5% | 586,807 | +2.2% | 0.01% | -22.2% |
| Q1 2022 | $9,338,000 | +20.3% | 574,249 | +2.5% | 0.02% | +20.0% |
| Q4 2021 | $7,764,000 | +6.1% | 560,499 | +10.0% | 0.02% | 0.0% |
| Q3 2021 | $7,320,000 | +11.3% | 509,469 | +22.5% | 0.02% | +7.1% |
| Q2 2021 | $6,575,000 | +66.3% | 415,845 | +7.0% | 0.01% | +40.0% |
| Q1 2021 | $3,953,000 | +68.5% | 388,697 | +23.5% | 0.01% | +66.7% |
| Q4 2020 | $2,346,000 | +315.2% | 314,834 | +91.3% | 0.01% | +200.0% |
| Q3 2020 | $565,000 | +20.0% | 164,593 | +66.5% | 0.00% | 0.0% |
| Q2 2020 | $471,000 | +823.5% | 98,847 | +284.3% | 0.00% | – |
| Q1 2020 | $51,000 | – | 25,723 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 7,637,700 | $77,675,000 | 7.44% |
| Burrage Capital Management LLC | 864,916 | $8,796,000 | 7.13% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,367,670 | $24,079,000 | 3.61% |
| HealthCor Management, L.P. | 4,886,440 | $49,695,000 | 1.76% |
| Ghost Tree Capital, LLC | 500,000 | $5,085,000 | 1.20% |
| Integral Health Asset Management, LLC | 400,000 | $4,068,000 | 1.16% |
| Lisanti Capital Growth, LLC | 472,520 | $4,806,000 | 0.62% |
| Parkman Healthcare Partners LLC | 244,680 | $2,488,000 | 0.58% |
| Baker Brothers Advisors | 12,710,818 | $129,269,000 | 0.56% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,605,380 | $26,497,000 | 0.56% |